GeNeuro is an advanced pharmaceutical company focused on innovating the treatment of autoimmune conditions such as multiple sclerosis (MS) and Type 1 Diabetes (T1D) linked to pathogenic proteins expressed by human endogenous retroviruses (HERV), viral genes representing 8% of the human DNA. This innovative approach stems from 25 years of research on endogenous retroviruses, with 15 years conducted at Institut Mérieux and INSERM prior to the establishment of GeNeuro in 2006. Through this research, the company has identified a potentially causative factor for multiple sclerosis, known as the envelope protein (Env).
GENeuro
Headquarters
Switzerland